Using Finasteride as Preventive Does Not Raise Chances of Dying from Prostate Cancer, Analysis Contends

Using Finasteride as Preventive Does Not Raise Chances of Dying from Prostate Cancer, Analysis Contends
Using finasteride to prevent prostate cancer does not raise the chances of dying from the disease among men who develop it, a recent analysis of the Prostate Cancer Prevention Trial (PCPT) shows. The study addresses concerns that prophylaxis (preventive use) with finasteride would raise men's probability of having a more aggressive cancer and reduce their chances of survival. "Finasteride is safe, inexpensive, and effective as a preventive strategy for prostate cancer," Ian Thompson, Jr, MD, principal investigator of the PCPT for SWOG, said in a press release. PCPT, a large clinical trial testing the drug's effectiveness as preventive in prostate cancer, indicated the treatment delayed or prevented the appearance of the cancer by 23%; however, it increased men’s chances of having a more aggressive cancer. In this recent analysis, team members who led the study explained their conclusions in a letter to the editor, “
Subscribe or to access all post and page content.